- 2 -

IN THE SPECIFICATION

Please amend the specification as follows.

At p. 1, amend the first paragraph (lines 4-5) as follows:

et.

This application is a divisional application of, and claims the benefit of U.S. Application Serial No. 09/940,760, filed August 28, 2001, which claims the benefit of U.S. Provisional Application Serial No. 60,233,567, filed September 19, 2000.

At pp. 91-92, delete the following two paragraphs:

Furthermore, a representative inventive compound did not adversely react with nitrate medication in a rat. It is believed the same lack of adverse interaction will apply to all inventive compounds in all mammals, including humans. An adverse reaction with nitrate medication may be dangerous and fatal. Adverse reactions include any reaction that could jeopardize or otherwise diminish the body's physiological functions. More specifically, in the case of combination therapy for a patient, comprising administering to the patient a nitrate denating agent combined with a PDE V inhibitor agent, an adverse nitrate reaction would be one in which the patient's blood-pressure drops significantly more than with either agent administered alone.

This feature opens up a method of erectile dysfunction treatment to many patients who suffer from both an erectile dysfunction and a cardiovascular or other disease(s) that is treated with a nitrate denating medicament. Patients suffering from two-or-more different-ailments that require dual (or multiple) treatments may have been born with one or both ailments, or later developed one or both ailments due to genetics or some other type of injury or disease, such as nerve damage, spinal cord injury, diabetes, and the like. Accordingly, it is another embodiment of this invention to treat a patient-suffering from both (1) an erectile dysfunction and (2) at least one-condition that can be treated with a nitrate donor medication, the inventive treatment comprising, a combination therapy comprising, an-administration to a mammal of at least one inventive compound or a pharmaceutical composition thereof, and at least one nitrate denating compound or a pharmaceutical composition thereof. The patient suffering from both crectile dysfunction and a need for a nitrate denating medicament can be treated for both conditions sequentially, concurrently and/or simultaneously. The combination therapy can be taken separately in any form, preferably in oral or patch doses, or can be fermulated together for a single, combined desage.